Risk Factors for the Development and Progression of Carcinoid Heart Disease

被引:92
作者
Bhattacharyya, Sanjeev [1 ]
Toumpanakis, Christos [2 ]
Chilkunda, Deepika [2 ]
Caplin, Martyn Evan [2 ]
Davar, Joseph [1 ]
机构
[1] Carcinoid Heart Dis Clin, Dept Cardiol, London, England
[2] Royal Free Hosp, Neuroendocrine Tumour Unit, London NW3 2QG, England
关键词
CONSENSUS GUIDELINES; MANAGEMENT; GROWTH; TUMORS;
D O I
10.1016/j.amjcard.2010.12.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The development of valvular heart disease in patients with carcinoid syndrome is thought to be related to the secretion of vasoactive substances by a tumor. We sought to identify modifiable risk factors for the development of carcinoid heart disease because this may help define strategies to attenuate the disease process. Two hundred fifty-two patients with carcinoid syndrome were prospectively followed with serial echocardiograms at 6-month intervals. Clinical characteristics, biochemical markers, and radiologic markers were measured at set intervals. An echocardiographic scoring system was applied. Patients were defined as having progression of carcinoid heart disease if the echocardiographic score increased by >= 25%. After a median follow-up of 29 months, 44 patients developed carcinoid heart disease or had progression of existing valvular dysfunction. At time of progression of carcinoid heart disease compared to the previous 6 months, there was a significant increase in median levels of 5-hydroxyindoleacetic acid (5-HIAA; 791 vs 460.5 mu mol/24 hours) and flushing episodes (4.5 vs 2 episodes per day). Independent predictors of the development or progression of carcinoid heart disease were a 5-HIAA level >= 300 mu mol/24 hours and >= 3 episodes of flushing per day. 5-HIAA levels of >= 300 to 599, 600 to 899, and >900 mu mol/24 hours conferred 2.74, 3.16, and 3.40 times the risk of progression of carcinoid heart disease, respectively. In conclusion, a 5-HIAA level >= 300 mu mol/24 hours and >= 3 flushing episodes per day are predictors of the development or progression of carcinoid heart disease. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107: 1221-1226)
引用
收藏
页码:1221 / 1226
页数:6
相关论文
共 26 条
  • [1] Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice
    Baumgartner, Helmut
    Hung, Judy
    Bermejo, Javier
    Chambers, John B.
    Evangelista, Arturo
    Griffin, Brian P.
    Iung, Bernard
    Otto, Catherine M.
    Pellikka, Patricia A.
    Quinones, Miguel
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2009, 22 (01) : 1 - 23
  • [2] Bernheim AM, 2008, MAYO CLIN PROC, V83, P143, DOI 10.4065/83.2.143
  • [3] Carcinoid heart disease
    Bhattacharyya, Sanjeev
    Davar, Joseph
    Dreyfus, Gilles
    Caplin, Martyn E.
    [J]. CIRCULATION, 2007, 116 (24) : 2860 - 2865
  • [4] Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study
    Cwikla, J. B.
    Sankowski, A.
    Seklecka, N.
    Buscombe, J. R.
    Nasierowska-Guttmejer, A.
    Jeziorski, K. G.
    Mikolajczak, R.
    Pawlak, D.
    Stepien, K.
    Walecki, J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (04) : 787 - 794
  • [5] Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease
    Denney, WD
    Kemp, WE
    Anthony, LB
    Oates, JA
    Byrd, BF
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (04) : 1017 - 1022
  • [6] Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors
    Drougas, JG
    Anthony, LB
    Blair, TK
    Lopez, RR
    Wright, JK
    Chapman, WC
    Webb, L
    Mazer, M
    Meranze, S
    Pinson, CW
    [J]. AMERICAN JOURNAL OF SURGERY, 1998, 175 (05) : 408 - 412
  • [7] Consensus guidelines for the management of patients with digestive neuroendocrine tumors -: Well-differentiated jejunal-ileal tumor/carcinoma
    Eriksson, Barbro
    Kloeppel, Guenter
    Krenning, Eric
    Ahlman, Hakan
    Ploeckinger, Ursula
    Wiedenmann, Bertram
    Arnold, Rudolf
    Auernhammer, Christoph
    Koerner, Meike
    Rindi, Guido
    Wildi, Stefan
    [J]. NEUROENDOCRINOLOGY, 2008, 87 (01) : 8 - 19
  • [8] Eriksson BK, 1998, CANCER, V83, P2293, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2293::AID-CNCR8>3.0.CO
  • [9] 2-E
  • [10] Long-term serotonin administration induces heart valve disease in rats
    Gustafsson, BI
    Tommerås, K
    Nordrum, I
    Loennechen, JP
    Brunsvik, A
    Solligård, E
    Fossmark, R
    Bakke, I
    Syversen, U
    Waldum, H
    [J]. CIRCULATION, 2005, 111 (12) : 1517 - 1522